ImmuneOnco Biopharmaceuticals (Shanghai) Inc.’s (HKG:1541) 9.3% loss last week hit both individual investors who own 46% as well as institutions

Key Insights

Trump has pledged to “unleash” American oil and gas and these 15 US stocks have developments that are poised to benefit.

A look at the shareholders of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) can tell us which group is most powerful. We can see that retail investors own the lion’s share in the company with 46% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

While institutions, who own 18% shares weren’t spared from last week’s HK$452m market cap drop, retail investors as a group suffered the maximum losses

In the chart below, we zoom in on the different ownership groups of ImmuneOnco Biopharmaceuticals (Shanghai).

See our latest analysis for ImmuneOnco Biopharmaceuticals (Shanghai)

What Does The Institutional Ownership Tell Us About ImmuneOnco Biopharmaceuticals (Shanghai)?

…